Multitask machine learning and feature selection for biomarker discovery from big biological data.

Proteins and metabolites, the new class of biomarkers are expected to bring a paradigm shift in the diagnosis, monitoring and treatment of human disease and will make personalized medicine a reality in near future.  Moreover, the next generation biomarkers are likely to be based on the inference drawn from multiple metabolite or protein molecules rather than single measurements such as the blood glucose level that is currently used for the diagnosis of diabetes.

Synthetic biology and metabolic engineering of cyanobacteria

Cyanobacteria or blue-green algae are a group of prokaryotes well known for their ability to carry out oxygenic photosynthesis. These photoautotrophs show greater photosynthetic efficiency, simpler genetic structures and faster growth compared to terrestrial plants and green algae.  Moreover, cyanobacteria can be engineered genetically and can grow on non-arable land, waste-water and seawater.  These properties make cyanobacteria an interesting host for biotechnological applications.

Human metabolomics for precision medicine.

Metabolomics, or the study of all cellular metabolites, promises to be a new cornerstone in disease diagnosis and precision medicine.  Several recent reports demonstrate that metabolite profiles are excellent indicators of the health status of individuals.  In addition, metabolomics monitoring is likely to be included in the clinical trials on a routine basis.  Most of these reports are with Caucasian patients with almost no data available for the Indian population.  Furthermore, the field of metabolomics is not nearly as developed as proteomics or transcriptom